In patients with MASLD, LCDs demonstrate clinically meaningful improvements in insulin sensitivity, adiposity, and dyslipidemia, particularly when carbohydrate intake is restricted below 26% of total energy. The gene discussed is INS; the disease is metabolic syndrome.